BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ballestri S, Nascimbeni F, Romagnoli D, Baldelli E, Targher G, Lonardo A. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. Int J Mol Sci. 2016;17:355. [PMID: 27005620 DOI: 10.3390/ijms17030355] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Mirarchi L, Amodeo S, Citarrella R, Licata A, Soresi M, Giannitrapani L. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. IJMS 2022;23:3668. [DOI: 10.3390/ijms23073668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
2 Albhaisi S, Sanyal AJ. Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne) 2021;12:665987. [PMID: 34040583 DOI: 10.3389/fendo.2021.665987] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Ballestri S, Mantovani A, Baldelli E, Lugari S, Maurantonio M, Nascimbeni F, Marrazzo A, Romagnoli D, Targher G, Lonardo A. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. Diagnostics (Basel) 2021;11:98. [PMID: 33435415 DOI: 10.3390/diagnostics11010098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 15.5] [Reference Citation Analysis]
4 Bellesini M, Bianchin M, Corradi C, Donadini MP, Raschi E, Squizzato A. Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: Looking for Evidence Through a Systematic Review. Clin Drug Investig 2020;40:1001-8. [PMID: 32809123 DOI: 10.1007/s40261-020-00962-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
5 Huanan C, Sangsang L, Amoah AN, Yacong B, Xuejiao C, Zhan S, Guodong W, Jian H, Songhe S, Quanjun L. Relationship between triglyceride glucose index and the incidence of non-alcoholic fatty liver disease in the elderly: a retrospective cohort study in China. BMJ Open 2020;10:e039804. [PMID: 33247011 DOI: 10.1136/bmjopen-2020-039804] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
6 Zheng Q, Martin RC, Shi X, Pandit H, Yu Y, Liu X, Guo W, Tan M, Bai O, Meng X, Li Y. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics 2020;10:9923-36. [PMID: 32929325 DOI: 10.7150/thno.45988] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
7 Ye L, He S, Mao X, Zhang Y, Cai Y, Li S. Effect of Hepatic Macrophage Polarization and Apoptosis on Liver Ischemia and Reperfusion Injury During Liver Transplantation. Front Immunol 2020;11:1193. [PMID: 32676077 DOI: 10.3389/fimmu.2020.01193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 13.0] [Reference Citation Analysis]
8 Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Lonardo A. Extra-hepatic manifestations and complications of nonalcoholic fatty liver disease. Future Med Chem 2019;11:2171-92. [PMID: 31538528 DOI: 10.4155/fmc-2019-0003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
9 da Silva CB, Vieira DA, de Melo LF, Chagas ALS, Gomes AD, Faria Jr CLL, Teixeira R, de Magalhães Queiroz DM, Rocha GA, Soares MMS, Bezerra JMT, Silva LD. Interleukin-6-174G/C polymorphism is associated with a decreased risk of type 2 diabetes in patients with chronic hepatitis C virus. World J Hepatol 2020; 12(4): 137-148 [PMID: 32685106 DOI: 10.4254/wjh.v12.i4.137] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Koutny F, Weghuber D, Bollow E, Greber-Platzer S, Hartmann K, Körner A, Reinehr T, Roebl M, Simic-Schleicher G, Wabitsch M, Widhalm K, Wiegand S, Holl RW. Prevalence of prediabetes and type 2 diabetes in children with obesity and increased transaminases in European German-speaking countries. Analysis of the APV initiative. Pediatr Obes 2020;15:e12601. [PMID: 31810110 DOI: 10.1111/ijpo.12601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
11 Singh A, Elboraie A, Lan N, Gupta M. Factors Associated with Deep Vein Thrombosis in Type 2 Diabetics with Biopsy-Proven Non-alcoholic Fatty Liver Disease. SN Compr Clin Med 2020;2:32-41. [DOI: 10.1007/s42399-019-00188-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Mardinoglu A, Ural D, Zeybel M, Yuksel HH, Uhlén M, Borén J. The Potential Use of Metabolic Cofactors in Treatment of NAFLD. Nutrients 2019;11:E1578. [PMID: 31336926 DOI: 10.3390/nu11071578] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
13 Pacifico L, Perla FM, Roggini M, Andreoli G, D'Avanzo M, Chiesa C. A Systematic Review of NAFLD-Associated Extrahepatic Disorders in Youths. J Clin Med 2019;8:E868. [PMID: 31213030 DOI: 10.3390/jcm8060868] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
14 Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol 2019;70:531-44. [PMID: 30414863 DOI: 10.1016/j.jhep.2018.10.033] [Cited by in Crossref: 866] [Cited by in F6Publishing: 861] [Article Influence: 216.5] [Reference Citation Analysis]
15 Cui Z, Qin Q, Chen P, Wang J, Zhang S, Mei X, Xie B, Wang S. EFFECT OF DORSOMEDIAL HYPOTHALAMUS NEUROPEPTIDE Y KNOCKDOWN ON HEPATIC INSULIN SENSITIVITY. Acta Endocrinol (Buchar) 2019;-5:25-31. [PMID: 31149056 DOI: 10.4183/aeb.2019.25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Yen YH, Kuo FY, Kee KM, Chang KC, Tsai MC, Hu TH, Lu SN, Wang JH, Hung CH, Chen CH. Diabetes is associated with advanced fibrosis and fibrosis progression in non-genotype 3 chronic hepatitis C patients. Dig Liver Dis 2019;51:142-8. [PMID: 30076015 DOI: 10.1016/j.dld.2018.07.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Jamalat Y, Gamallat Y, Jaceline Gislaine PS, Meyiah A, Shopit A, Li H, Ahmed B, Chu P, Wang H, Li X, Peng J, Ma X, Tang Z. Phosphocreatine attenuates endoplasmic reticulum stress-mediated hepatocellular apoptosis ameliorates insulin resistance in diabetes model. Biochemical and Biophysical Research Communications 2018;506:611-8. [DOI: 10.1016/j.bbrc.2018.10.122] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
18 Weinstein AA, de Avila L, Paik J, Golabi P, Escheik C, Gerber L, Younossi ZM. Cognitive Performance in Individuals With Non-Alcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus. Psychosomatics 2018;59:567-74. [DOI: 10.1016/j.psym.2018.06.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
19 Cui G, Martin RC, Jin H, Liu X, Pandit H, Zhao H, Cai L, Zhang P, Li W, Li Y. Up-regulation of FGF15/19 signaling promotes hepatocellular carcinoma in the background of fatty liver. J Exp Clin Cancer Res. 2018;37:136. [PMID: 29973237 DOI: 10.1186/s13046-018-0781-8] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
20 Ružić M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brkić S, Abenavoli L. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med 2018;60:185-91. [PMID: 29856183 DOI: 10.23736/S0031-0808.18.03472-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 5.4] [Reference Citation Analysis]
21 Dibba P, Cholankeril R, Li AA, Patel M, Fayek M, Dibble C, Okpara N, Hines A, Ahmed A. Hepatitis C in Pregnancy. Diseases 2018;6:E31. [PMID: 29702563 DOI: 10.3390/diseases6020031] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
22 Farshadpour F, Taherkhani R, Ravanbod MR, Eghbali SS. Prevalence and Genotype Distribution of Hepatitis C Virus Infection among Patients with Type 2 Diabetes Mellitus. Med Princ Pract 2018;27:308-16. [PMID: 29621783 DOI: 10.1159/000488985] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
23 Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, Yang MJ, Lim SG, Kim S, Cheong JY, Cho SW. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis 2018;50:370-7. [PMID: 29398414 DOI: 10.1016/j.dld.2017.12.018] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 7.6] [Reference Citation Analysis]
24 Katsiki N, Athyros VG, Karagiannis A. Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt – results from the GUARD study. Curr Med Res Opin 2017;33:797-801. Current Medical Research and Opinion 2017;33:2261-2262. [DOI: 10.1080/03007995.2017.1333955] [Reference Citation Analysis]
25 Kawaguchi T, Koga H, Torimura T. Recent Advances in the Pathogenesis of Hepatitis C Virus-Related Non-Alcoholic Fatty Liver Disease and Its Impact on Patients Cured of Hepatitis C. Curr Hepatology Rep 2017;16:317-25. [DOI: 10.1007/s11901-017-0370-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
26 Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol 2017; 23(36): 6571-6592 [PMID: 29085206 DOI: 10.3748/wjg.v23.i36.6571] [Cited by in CrossRef: 108] [Cited by in F6Publishing: 114] [Article Influence: 18.0] [Reference Citation Analysis]
27 Lonardo A, Targher G. NAFLD: Is There Anything New under the Sun? Int J Mol Sci 2017;18:E1955. [PMID: 28895919 DOI: 10.3390/ijms18091955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of Dapagliflozin on Body Composition and Liver Tests in Patients with Nonalcoholic Steatohepatitis Associated with Type 2 Diabetes Mellitus: A Prospective, Open-label, Uncontrolled Study. Curr Ther Res Clin Exp. 2017;87:13-19. [PMID: 28912902 DOI: 10.1016/j.curtheres.2017.07.002] [Cited by in Crossref: 77] [Cited by in F6Publishing: 84] [Article Influence: 12.8] [Reference Citation Analysis]
29 Manickam C, Wachtman L, Martinot AJ, Giavedoni LD, Reeves RK. Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). PLoS One 2017;12:e0170240. [PMID: 28085952 DOI: 10.1371/journal.pone.0170240] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Zhubanchaliyev A, Temirbekuly A, Kongrtay K, Wanshura LC, Kunz J. Targeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver Fibrosis. Front Pharmacol 2016;7:462. [PMID: 27990121 DOI: 10.3389/fphar.2016.00462] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
31 Lonardo A, Ballestri S, Guaraldi G, Nascimbeni F, Romagnoli D, Zona S, Targher G. Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. World J Gastroenterol 2016; 22(44): 9674-9693 [PMID: 27956792 DOI: 10.3748/wjg.v22.i44.9674] [Cited by in CrossRef: 79] [Cited by in F6Publishing: 83] [Article Influence: 11.3] [Reference Citation Analysis]